Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Douglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S Kapner, Michael H Rosenthal, Bryanna L Norden, Haley Barnes, Sara Ehnstrom, Alvin A Morales-Giron, Lauren K Brais, Christopher T Lemke, Andrew J Aguirre, Ryan B Corcoran
KRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Since amino acid sequences of the three main RAS isoforms-KRAS, NRAS and HRAS-are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but critical oncogenic driver mutations in some tumors. While some inhibitors, like adagrasib, were highly selective for KRASG12C, others also potently inhibited NRASG12C and/or HRASG12C...
January 18, 2024: Cancer Discovery
#2
JOURNAL ARTICLE
Samantha E Hoffman, Todd W Dowrey, Carlos Villacorta Martin, Kevin Bi, Breanna Titchen, Shreya Johri, Laura DelloStritto, Miraj Patel, Colin Mackichan, Stephanie Inga, Judy Chen, Grace Grimaldi, Sara Napolitano, Isaac Wakiro, Jingyi Wu, Jason Yeung, Asaf Rotem, Ewa Sicinska, Erin Shannon, Thomas Clancy, Jiping Wang, Sarah Denning, Lauren Brais, Naomi R Besson, Kathleen L Pfaff, Ying Huang, Katrina Z Kao, Scott Rodig, Jason L Hornick, Sebastien Vigneau, Jihye Park, Matthew H Kulke, Jennifer Chan, Eliezer M Van Allen, George J Murphy
Neuroendocrine tumors (NETs) are rare cancers that most often arise in the gastrointestinal tract and pancreas. The fundamental mechanisms driving gastroenteropancreatic (GEP)-NET growth remain incompletely elucidated; however, the heterogeneous clinical behavior of GEP-NETs suggests that both cellular lineage dynamics and tumor microenvironment influence tumor pathophysiology. Here, we investigated the single-cell transcriptomes of tumor and immune cells from patients with gastroenteropancreatic NETs. Malignant GEP-NET cells expressed genes and regulons associated with normal, gastrointestinal endocrine cell differentiation, and fate determination stages...
September 29, 2023: Science Advances
#3
JOURNAL ARTICLE
Vincenzo Graziano, Andreas Dannhorn, Heather Hulme, Kate Williamson, Hannah Buckley, Saadia A Karim, Matthew Wilson, Sheng Y Lee, Brajesh P Kaistha, Sabita Islam, James E D Thaventhiran, Frances M Richards, Richard Goodwin, Rebecca Brais, Jennifer P Morton, Simon J Dovedi, Alwin G Schuller, Jim Eyles, Duncan I Jodrell
BACKGROUND: The prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) remains extremely poor. It has been suggested that the adenosine pathway contributes to the ability of PDAC to evade the immune system and hence, its resistance to immuno-oncology therapies (IOT), by generating extracellular adenosine (eAdo). METHODS: Using genetically engineered allograft models of PDAC in syngeneic mice with defined and different immune infiltration and response to IOT and autochthonous tumors in KPC mice we investigated the impact of the adenosine pathway on the PDAC tumor microenvironment (TME)...
August 2023: Journal for Immunotherapy of Cancer
#4
JOURNAL ARTICLE
Harshabad Singh, Rachel B Keller, Kevin S Kapner, Julien Dilly, Srivatsan Raghavan, Chen Yuan, Elizabeth F Cohen, Michael Tolstorukov, Elizabeth Andrews, Lauren K Brais, Annacarolina da Silva, Kimberly Perez, Douglas A Rubinson, Rishi Surana, Marios Giannakis, Kimmie Ng, Thomas E Clancy, Matthew B Yurgelun, Benjamin L Schlechter, Jeffrey W Clark, Geoffrey I Shapiro, Michael H Rosenthal, Jason L Hornick, Valentina Nardi, Yvonne Y Li, Hersh Gupta, Andrew D Cherniack, Matthew Meyerson, James M Cleary, Jonathan A Nowak, Brian M Wolpin, Andrew J Aguirre
PURPOSE: Approximately 8-10% of pancreatic ductal adenocarcinomas (PDAC) do not harbor mutations in KRAS. Understanding the unique molecular and clinical features of this subset of pancreatic cancer is important to guide patient stratification for clinical trials of molecularly targeted agents. EXPERIMENTAL DESIGN: We analyzed a single-institution cohort of 795 exocrine pancreatic cancer cases (including 785 PDAC cases) with a targeted multi-gene sequencing panel and identified 73 patients (9...
July 18, 2023: Clinical Cancer Research
#5
JOURNAL ARTICLE
Victoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, S Jennifer Wang, Lauren K Brais, Joshua Remland, C Elizabeth Keheler, Keri M Sullivan, Thomas A Abrams, Leah H Biller, Peter C Enzinger, Nadine J McCleary, Anuj K Patel, Douglas A Rubinson, Benjamin Schlechter, Sarah Slater, Matthew B Yurgelun, James M Cleary, Kimberly Perez, Michael Dougan, Kimmie Ng, Brian M Wolpin, Harshabad Singh, Stephanie K Dougan
BACKGROUND: Recombinant granulocyte colony-stimulating factor (G-CSF) is routinely administered for prophylaxis or treatment of chemotherapy-induced neutropenia. Chronic myelopoiesis and granulopoiesis in patients with cancer has been shown to induce immature monocytes and neutrophils that contribute to both systemic and local immunosuppression in the tumor microenvironment. The effect of recombinant G-CSF (pegfilgrastim or filgrastim) on the production of myeloid-derived suppressive cells is unknown...
June 2023: Journal for Immunotherapy of Cancer
#6
JOURNAL ARTICLE
Harshabad Singh, Samuel J Klempner, Nelya Melnitchouk, Deepak P Chander, Ovidiu George Negrea, Anuj K Patel, Benjamin L Schlechter, Douglas A Rubinson, Brandon M Huffman, Chetan Nambiar, Joshua Remland, Elizabeth Andrews, Megan E Leahy, Lauren K Brais, Peter C Enzinger, Harvey J Mamon, Marios Giannakis, Jeffrey A Meyerhardt, Kimmie Ng, Kimberly J Perez, Andrew J Aguirre, Jeffrey W Clark, James M Cleary, Brian M Wolpin
PURPOSE: GI cancers commonly spread to the peritoneal cavity, particularly from primary adenocarcinomas of the stomach and appendix. Peritoneal metastases are difficult to visualize on cross-sectional imaging and cause substantial morbidity and mortality. The purpose of this study was to determine whether serial highly sensitive tumor-informed circulating tumor DNA (ctDNA) measurements could longitudinally track changes in disease burden and inform clinical care. METHODS: This was a retrospective case series of patients with gastric or appendiceal adenocarcinoma and isolated peritoneal disease that was radiographically occult...
June 2023: JCO Precision Oncology
#7
JOURNAL ARTICLE
Kimberly Perez, Anna M Chiarella, James M Cleary, Nora Horick, Colin Weekes, Thomas Abrams, Lawrence Blaszkowsky, Peter Enzinger, Marios Giannakis, Lipika Goyal, Jeffrey A Meyerhardt, Douglas Rubinson, Matthew B Yurgelun, Wolfram Goessling, Bruce J Giantonio, Lauren Brais, Victoria Germon, Danielle Stonely, Srivatsan Raghavan, Basil Bakir, Koushik Das, Jason R Pitarresi, Andrew J Aguirre, Michael Needle, Anil K Rustgi, Brian M Wolpin
BACKGROUND: In preclinical pancreatic ductal adenocarcinoma (PDAC) models, inhibition of hepatocyte growth factor (HGF) signaling using ficlatuzumab, a recombinant humanized anti-HGF antibody, and gemcitabine reduced tumor burden. METHODS: Patients with previously untreated metastatic PDAC enrolled in a phase Ib dose escalation study with 3 + 3 design of 2 dose cohorts of ficlatuzumab 10 and 20 mg/kg administered intravenously every other week with gemcitabine 1000 mg/m2 and albumin-bound paclitaxel 125 mg/m2 given 3 weeks on and 1 week off...
February 18, 2023: Oncologist
#8
JOURNAL ARTICLE
Rachel B Keller, Tali Mazor, Lynette Sholl, Andrew J Aguirre, Harshabad Singh, Nilay Sethi, Adam Bass, Ankur K Nagaraja, Lauren K Brais, Emma Hill, Connor Hennessey, Margaret Cusick, Catherine Del Vecchio Fitz, Zachary Zwiesler, Ethan Siegel, Andrea Ovalle, Pavel Trukhanov, Jason Hansel, Geoffrey I Shapiro, Thomas A Abrams, Leah H Biller, Jennifer A Chan, James M Cleary, Steven M Corsello, Andrea C Enzinger, Peter C Enzinger, Robert J Mayer, Nadine J McCleary, Jeffrey A Meyerhardt, Kimmie Ng, Anuj K Patel, Kimberley J Perez, Osama E Rahma, Douglas A Rubinson, Jeffrey S Wisch, Matthew B Yurgelun, Michael J Hassett, Laura MacConaill, Deborah Schrag, Ethan Cerami, Brian M Wolpin, Jonathan A Nowak, Marios Giannakis
PURPOSE: With the growing number of available targeted therapeutics and molecular biomarkers, the optimal care of patients with cancer now depends on a comprehensive understanding of the rapidly evolving landscape of precision oncology, which can be challenging for oncologists to navigate alone. METHODS: We developed and implemented a precision oncology decision support system, GI TARGET, (Gastrointestinal Treatment Assistance Regarding Genomic Evaluation of Tumors) within the Gastrointestinal Cancer Center at the Dana-Farber Cancer Institute...
January 2023: JCO Precision Oncology
#9
JOURNAL ARTICLE
Hannah L Williams, Andressa Dias Costa, Jinming Zhang, Srivatsan Raghavan, Peter S Winter, Kevin S Kapner, Scott P Ginebaugh, Sara A Väyrynen, Juha P Väyrynen, Chen Yuan, Andrew W Navia, Junning Wang, Annan Yang, Timothy L Bosse, Radha L Kalekar, Kristen E Lowder, Mai Chan Lau, Dalia Elganainy, Vicente Morales-Oyarvide, Douglas A Rubinson, Harshabad Singh, Kimberly Perez, James M Cleary, Thomas E Clancy, Jiping Wang, Joseph D Mancias, Lauren K Brais, Emma R Hill, Margaret M Kozak, David C Linehan, Richard F Dunne, Daniel T Chang, Albert C Koong, Aram F Hezel, William C Hahn, Alex K Shalek, Andrew J Aguirre, Jonathan A Nowak, Brian M Wolpin
Pancreatic ductal adenocarcinoma (PDAC) has been classified into classical and basal-like transcriptional subtypes by bulk RNA measurements. However, recent work has uncovered greater complexity to transcriptional subtypes than was initially appreciated using bulk RNA expression profiling. To provide a deeper understanding of PDAC subtypes, we developed a multiplex immunofluorescence (mIF) pipeline that quantifies protein expression of six PDAC subtype markers (CLDN18.2, TFF1, GATA6, KRT17, KRT5, and S100A2) and permits spatially resolved, single-cell interrogation of pancreatic tumors from resection specimens and core needle biopsies...
December 2, 2022: Cancer Research
#10
JOURNAL ARTICLE
Andressa Dias Costa, Sara A Väyrynen, Akhil Chawla, Jinming Zhang, Juha P Väyrynen, Mai Chan Lau, Hannah L Williams, Chen Yuan, Vicente Morales-Oyarvide, Dalia Elganainy, Harshabad Singh, James M Cleary, Kimberly Perez, Kimmie Ng, William Freed-Pastor, Joseph D Mancias, Stephanie K Dougan, Jiping Wang, Douglas A Rubinson, Richard F Dunne, Margaret M Kozak, Lauren Brais, Emma Reilly, Thomas Clancy, David C Linehan, Daniel T Chang, Aram F Hezel, Albert C Koong, Andrew J Aguirre, Brian M Wolpin, Jonathan A Nowak
PURPOSE: Neoadjuvant chemotherapy is increasingly administered to patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC), yet its impact on the tumor immune microenvironment is incompletely understood. DESIGN: We employed quantitative, spatially resolved multiplex immunofluorescence and digital image analysis to identify T-cell subpopulations, macrophage polarization states, and myeloid cell subpopulations in a multi-institution cohort of up-front resected primary tumors (n = 299) and in a comparative set of resected tumors after FOLFIRINOX-based neoadjuvant therapy (n = 36) or up-front surgery (n = 30)...
December 1, 2022: Clinical Cancer Research
#11
JOURNAL ARTICLE
Kimberly Perez, Heather Jacene, Jason L Hornick, Chao Ma, Nuno Vaz, Lauren K Brais, Holly Alexander, William Baddoo, Kristina Astone, Edward D Esplin, John Garcia, Daniel M Halperin, Matthew H Kulke, Jennifer A Chan
Malignant pheochromocytomas (PHEOs)/paragangliomas (PGLs) are rare tumors for which clinical outcomes remain poorly defined and therapeutic options are limited. Approximately 27% carry pathogenic germline succinate dehydrogenase (SDHx) mutations; the presence of such mutations has been correlated with response to temozolomide (TMZ). We aimed to investigate the association between germline mutations in SDHx and response to TMZ. We retrospectively identified patients with metastatic malignant PHEO/PGLs treated with TMZ- based chemotherapy at Dana-Farber Cancer Institute between 2003 and 2020...
September 1, 2022: Endocrine-related Cancer
#12
JOURNAL ARTICLE
Giulia Bononi, Miriana Di Stefano, Giulio Poli, Gabriella Ortore, Philip Meier, Francesca Masetto, Isabella Caligiuri, Flavio Rizzolio, Marco Macchia, Andrea Chicca, Amir Avan, Elisa Giovannetti, Chiara Vagaggini, Annalaura Brai, Elena Dreassi, Massimo Valoti, Filippo Minutolo, Carlotta Granchi, Jürg Gertsch, Tiziano Tuccinardi
Monoacylglycerol lipase (MAGL) is the enzyme responsible for the metabolism of 2-arachidonoylglycerol in the brain and the hydrolysis of peripheral monoacylglycerols. Many studies demonstrated beneficial effects deriving from MAGL inhibition for neurodegenerative diseases, inflammatory pathologies, and cancer. MAGL expression is increased in invasive tumors, furnishing free fatty acids as pro-tumorigenic signals and for tumor cell growth. Here, a new class of benzylpiperidine-based MAGL inhibitors was synthesized, leading to the identification of 13 , which showed potent reversible and selective MAGL inhibition...
May 26, 2022: Journal of Medicinal Chemistry
#13
JOURNAL ARTICLE
Asael Lubotzky, Hai Zemmour, Daniel Neiman, Marc Gotkine, Netanel Loyfer, Sheina Piyanzin, Bracha-Lea Ochana, Roni Lehmann-Werman, Daniel Cohen, Joshua Moss, Judith Magenheim, Maureen F Loftus, Lauren Brais, Kimmie Ng, Raul Mostoslavsky, Brian M Wolpin, Aviad Zick, Myriam Maoz, Albert Grinshpun, Anatoli Kustanovich, Chen Makranz, Jonathan E Cohen, Tamar Peretz, Ayala Hubert, Mark Temper, Azzam Salah, Shani Avniel-Polak, Simona Grozinsky-Glasberg, Kirsty L Spalding, Ariel Rokach, Tommy Kaplan, Benjamin Glaser, Ruth Shemer, Yuval Dor
Cancer inflicts damage to surrounding normal tissues, which can culminate in fatal organ failure. Here, we demonstrate that cell death in organs affected by cancer can be detected by tissue-specific methylation patterns of circulating cell-free DNA (cfDNA). We detected elevated levels of hepatocyte-derived cfDNA in the plasma of patients with liver metastases originating from different primary tumors, compared with cancer patients without liver metastases. In addition, patients with localized pancreatic or colon cancer showed elevated hepatocyte cfDNA, suggesting liver damage inflicted by micrometastatic disease, by primary pancreatic tumor pressing the bile duct, or by a systemic response to the primary tumor...
January 25, 2022: JCI Insight
#14
JOURNAL ARTICLE
Nicole Strittmatter, Frances M Richards, Alan M Race, Stephanie Ling, Daniel Sutton, Anna Nilsson, Yann Wallez, Jennifer Barnes, Gareth Maglennon, Aarthi Gopinathan, Rebecca Brais, Edmond Wong, Maria Paola Serra, James Atkinson, Aaron Smith, Joanne Wilson, Gregory Hamm, Timothy I Johnson, Charles R Dunlop, Brajesh P Kaistha, Josephine Bunch, Owen J Sansom, Zoltan Takats, Per E Andrén, Alan Lau, Simon T Barry, Richard J A Goodwin, Duncan I Jodrell
Gemcitabine (dFdC) is a common treatment for pancreatic cancer; however, it is thought that treatment may fail because tumor stroma prevents drug distribution to tumor cells. Gemcitabine is a pro-drug with active metabolites generated intracellularly; therefore, visualizing the distribution of parent drug as well as its metabolites is important. A multimodal imaging approach was developed using spatially coregistered mass spectrometry imaging (MSI), imaging mass cytometry (IMC), multiplex immunofluorescence microscopy (mIF), and hematoxylin and eosin (H&E) staining to assess the local distribution and metabolism of gemcitabine in tumors from a genetically engineered mouse model of pancreatic cancer (KPC) allowing for comparisons between effects in the tumor tissue and its microenvironment...
January 25, 2022: Analytical Chemistry
#15
JOURNAL ARTICLE
Kimberly Perez, Matthew H Kulke, Anu Chittenden, Chinedu Ukaegbu, Kristina Astone, Holly Alexander, Lauren Brais, Jinming Zhang, John Garcia, Edward D Esplin, Shan Yang, Annacarolina Da Silva, Jonathan A Nowak, Matthew B Yurgelun, Judy Garber, Sapna Syngal, Jennifer Chan
PURPOSE: An inherited basis for presumed sporadic neuroendocrine tumor (NET) has been suggested by evidence of familial clustering of NET and a higher incidence of second malignancies in patients and families with NET. To further investigate a potential heritable basis for sporadic neuroendocrine tumors, we performed multigene platform germline analysis to determine the frequency of hereditary susceptibility gene variants in a cohort of patients with sporadic small intestine NET (SI-NET)...
November 2021: JCO Precision Oncology
#16
JOURNAL ARTICLE
Srivatsan Raghavan, Peter S Winter, Andrew W Navia, Hannah L Williams, Alan DenAdel, Kristen E Lowder, Jennyfer Galvez-Reyes, Radha L Kalekar, Nolawit Mulugeta, Kevin S Kapner, Manisha S Raghavan, Ashir A Borah, Nuo Liu, Sara A Väyrynen, Andressa Dias Costa, Raymond W S Ng, Junning Wang, Emma K Hill, Dorisanne Y Ragon, Lauren K Brais, Alex M Jaeger, Liam F Spurr, Yvonne Y Li, Andrew D Cherniack, Matthew A Booker, Elizabeth F Cohen, Michael Y Tolstorukov, Isaac Wakiro, Asaf Rotem, Bruce E Johnson, James M McFarland, Ewa T Sicinska, Tyler E Jacks, Ryan J Sullivan, Geoffrey I Shapiro, Thomas E Clancy, Kimberly Perez, Douglas A Rubinson, Kimmie Ng, James M Cleary, Lorin Crawford, Scott R Manalis, Jonathan A Nowak, Brian M Wolpin, William C Hahn, Andrew J Aguirre, Alex K Shalek
Prognostically relevant RNA expression states exist in pancreatic ductal adenocarcinoma (PDAC), but our understanding of their drivers, stability, and relationship to therapeutic response is limited. To examine these attributes systematically, we profiled metastatic biopsies and matched organoid models at single-cell resolution. In vivo, we identify a new intermediate PDAC transcriptional cell state and uncover distinct site- and state-specific tumor microenvironments (TMEs). Benchmarking models against this reference map, we reveal strong culture-specific biases in cancer cell transcriptional state representation driven by altered TME signals...
December 9, 2021: Cell
#17
JOURNAL ARTICLE
Annalaura Brai, Valentina Riva, Letizia Clementi, Lucia Falsitta, Claudio Zamperini, Virginia Sinigiani, Claudio Festuccia, Samantha Sabetta, Davide Aiello, Camilla Roselli, Anna Garbelli, Claudia Immacolata Trivisani, Laura Maccari, Francesca Bugli, Maurizio Sanguinetti, Pierpaolo Calandro, Mario Chiariello, Paola Quaranta, Lorenzo Botta, Adriano Angelucci, Giovanni Maga, Maurizio Botta
DDX3X is an ATP-dependent RNA helicase that has recently attracted interest for its involvement in viral replication and oncogenic progression. Starting from hit compounds previously identified by our group, we have designed and synthesized a new series of DDX3X inhibitors that effectively blocked its helicase activity. These new compounds were able to inhibit the proliferation of cell lines from different cancer types, also in DDX3X low-expressing cancer cell lines. According to the absorption, distribution, metabolism, elimination properties, and antitumoral activity, compound BA103 was chosen to be further investigated in glioblastoma models...
November 7, 2021: Cancers
#18
JOURNAL ARTICLE
Leonie K de Klerk, Anuj K Patel, Sarah Derks, Eirini Pectasides, Jeremy Augustin, Mohamed Uduman, Nihal Raman, Fahire G Akarca, Nadine J McCleary, James M Cleary, Douglas A Rubinson, Jeffrey W Clark, Bridget Fitzpatrick, Lauren K Brais, Megan E Cavanaugh, Amanda J Rode, Melissa G Jean, Patrick H Lizotte, Matthew J Nazzaro, Mariano Severgnini, Hui Zheng, Charles S Fuchs, Peter C Enzinger, Adam J Bass
BACKGROUND: Immune checkpoint inhibitors have revolutionized cancer treatment, but the benefits in refractory patients with esophageal cancer have been modest. Predictors of response as well as new targets for novel therapeutic combinations are needed. In this phase 2 clinical trial, we tested single-agent pembrolizumab in patients with advanced esophageal cancer, who received at least one prior line of therapy. METHODS: Pembrolizumab 200 mg every 3 weeks was tested in 49 patients with refractory esophageal cancer: 39 with adenocarcinoma and 10 with esophageal squamous cell carcinoma...
September 2021: Journal for Immunotherapy of Cancer
#19
JOURNAL ARTICLE
Karin Pelka, Matan Hofree, Jonathan H Chen, Siranush Sarkizova, Joshua D Pirl, Vjola Jorgji, Alborz Bejnood, Danielle Dionne, William H Ge, Katherine H Xu, Sherry X Chao, Daniel R Zollinger, David J Lieb, Jason W Reeves, Christopher A Fuhrman, Margaret L Hoang, Toni Delorey, Lan T Nguyen, Julia Waldman, Max Klapholz, Isaac Wakiro, Ofir Cohen, Julian Albers, Christopher S Smillie, Michael S Cuoco, Jingyi Wu, Mei-Ju Su, Jason Yeung, Brinda Vijaykumar, Angela M Magnuson, Natasha Asinovski, Tabea Moll, Max N Goder-Reiser, Anise S Applebaum, Lauren K Brais, Laura K DelloStritto, Sarah L Denning, Susannah T Phillips, Emma K Hill, Julia K Meehan, Dennie T Frederick, Tatyana Sharova, Abhay Kanodia, Ellen Z Todres, Judit Jané-Valbuena, Moshe Biton, Benjamin Izar, Conner D Lambden, Thomas E Clancy, Ronald Bleday, Nelya Melnitchouk, Jennifer Irani, Hiroko Kunitake, David L Berger, Amitabh Srivastava, Jason L Hornick, Shuji Ogino, Asaf Rotem, Sébastien Vigneau, Bruce E Johnson, Ryan B Corcoran, Arlene H Sharpe, Vijay K Kuchroo, Kimmie Ng, Marios Giannakis, Linda T Nieman, Genevieve M Boland, Andrew J Aguirre, Ana C Anderson, Orit Rozenblatt-Rosen, Aviv Regev, Nir Hacohen
Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd) tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors. To understand the rules governing these varied responses, we transcriptionally profiled 371,223 cells from colorectal tumors and adjacent normal tissues of 28 MMRp and 34 MMRd individuals. Analysis of 88 cell subsets and their 204 associated gene expression programs revealed extensive transcriptional and spatial remodeling across tumors...
September 2, 2021: Cell
#20
JOURNAL ARTICLE
Anuj K Patel, Ritika Abhyankar, Lauren K Brais, Mei Sheng Duh, Victoria E Barghout, Lynn Huynh, Mihran A Yenikomshian, Kimmie Ng, Charles S Fuchs
BACKGROUND: Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for patients with refractory metastatic colorectal cancer (mCRC); limited comparative effectiveness data exist. MATERIALS AND METHODS: A retrospective, longitudinal cohort study of patients with mCRC who initiated FTD/TPI or regorafenib (index therapy) between 2012 and 2017 at a U.S. tertiary oncology center, Dana-Farber Cancer Institute, was conducted. Using best tumor response assessments, real-world overall response rates (rwORR) and disease control rates (rwDCR) were described and analyzed using logistic regression...
December 2021: Oncologist
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
